The Michael J. Fox Foundation for Parkinson's Research
  Research
  News & Events
  Funding Programs
  About

PD Online Research

Alzheimer Research Forum
  Current Papers
  ARF Recommends
  Research News
PDGene - Gene overview of all published PD-association studies for APOE
Back Search Methods Disclaimer Credits
 Gene: APOE  (AD2; MGC1571; apoprotein)  Entrez Gene    View on ALSGene   View on AlzGene   View on MSGene   View on SZGene
 Protein: apolipoprotein E  (Alzheimer disease 2)  ProteinLink
 Chromosome: 19   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 27 November 2011
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      PD Cases Normal Controls  
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
 Caucasian
Ballering, 1997
Overlaps with
Ghebremedhin, 2006
CL  2  (detail)  50
(-)
M--107
(-)
-n.a.
Benjamin, 1994
UK CL  2  (detail)  23
(-)
---55
(-)
-Negative
Blazquez, 2006
Spain CL  2  (detail)  276
(41%)
C64.2 + 11.3
(-)
71.1 + 10.2
(-)
212
(48%)
70.9 + 8
(-)
Positive
Bon, 1999
Overlaps with
Ghebremedhin, 2006
CL  2  (detail)  50
(-)
N--96
(-)
-n.a.
Buchanan, 2006
Australia CL  2  (detail)  422
(43%)
C59.9 + 10.4
(-)
66.9 + 9.8
(-)
387
(71%)
64.1 + 10.8
(-)
Positive
Cramer, 2009
USA CL  2  (detail)  53
(36%)
C-65 + 10
(-)
54
(-)
55 + 15
(-)
Negative
Eerola, 2002
Finland CL  2  (detail)  147
(41%)
C-67.2
(38-88)
137
(64%)
65.8
(37-87)
Negative
Egensperger, 1996
Overlaps with
Grasbon-Frodl, 1999
CL  2  (detail)  20
(-)
M-76 + 6.2
(-)
54
(-)
71.2 + 9.5
(-)
n.a.
Egensperger, 1997
Overlaps with
Grasbon-Frodl, 1999
CL  2  (detail)  23
(35%)
M-75.5
(-)
100
(54%)
74.3
(-)
n.a.
Engelborghs, 2003
Belgium CL  2  (detail)  30
(43%)
C68.5 + 7.7
(-)
75.4 + 6.7
(59-90)
189
(54%)
58.8 + 16.9
(19-95)
Negative
Ezquerra, 2008
Spain CL  2  (detail)  138
(42%)
C-56 + 8.4
(-)
91
(56%)
67 + 9.2
(-)
Negative
Ferrarese, 2001
Italy CL  2  (detail)  38
(-)
C--28
(-)
-Negative
French Study Group, 1997
France CL  2  (detail)  103
(46%)
C57
(-)
65
(-)
387
(44%)
67 + 9
(-)
Positive
Fung, 2006
Overlaps with
Simon-Sanchez, 2009 (USA)
CL  1  (detail)  267
(-)
C--270
(-)
68
(55-88)
n.a.
Gao, 2011
USA (PAGE) PO  2  (detail)  786
(24%)
C65.7 + 7.5
(-)
-1537
(21%)
-Positive
Ghebremedhin, 2006
Netherlands CL  2  (detail)  108
(43%)
M65.8
(-)
75.1 + 6.9
(55-89)
108
(43%)
75.1 + 6.9
(55-89)
Positive
Grasbon-Frodl, 1999
Germany CL  2  (detail)  62
(53%)
M-70
(-)
53
(58%)
71
(-)
Negative
Hardy, 1994
UK CL  2  (detail)  24
(-)
N-75 + 7
(-)
46
(-)
-Negative
Harhangi, 2000
Netherlands PO  2  (detail)  81
(63%)
C-75.8 + 7.8
(-)
4805
(55%)
69 + 8.6
(-)
Positive
Harrington, 1994
UK & Belgium CL  2  (detail)  51
(49%)
N-77.7 + 7.1
(64-94)
58
(52%)
78.1 + 7.7
(60-91)
Negative
Helisalmi, 1996
Finland CL  2  (detail)  15
(47%)
C-71 + 6
(-)
60
(47%)
69 + 8
(-)
Negative
Ibarreta, 1995
Spain CL  2  (detail)  64
(-)
C-65.8 + 16
(44-90)
42
(-)
67.7 + 1.9
(52-90)
Negative
Khan, 2001
UK CL  2  (detail)  305
(45%)
M57
(-)
61 + 6
(-)
330
(47%)
63 + 7
(-)
Negative
Koller, 1995
USA CL  2  (detail)  61
(38%)
C-67.4 + 7.9
(-)
78
(53%)
69.9 + 6.5
(-)
Negative
Kruger, 1999
Overlaps with
Simon-Sanchez, 2009 (Germany)
CL  3  (detail)  236
(44%)
C-66.5 + 11
(-)
200
(-)
-n.a.
Kruger, 2000
Overlaps with
Schulte, 2003
CL  2  (detail)  191
(-)
C--293
(-)
-n.a.
Kurz, 2009
Overlaps with
Vefring, 2010 (Norway)
CL,PO  2  (detail)  95
(-)
M--73
(-)
-n.a.
Maraganore, 2000
USA CL  2  (detail)  139
(35%)
C62
(31-82)
69
(39-91)
113
(65%)
72
(37-90)
Negative
Martinoli, 1995
Canada CL  2  (detail)  10
(-)
N-69
(24-86)
243
(-)
-Negative
Mattila, 1998
Finland CL  2  (detail)  11
(45%)
M-71.9 + 6.8
(-)
59
(44%)
76
(-)
Negative
McCulloch, 2008
USA (Washington) CL  2  (detail)  391
(26%)
C-67.3
(32-95)
293
(58%)
67.3
(30-93)
Positive
McCulloch, 2008
USA (Oregon) CL  2  (detail)  172
(38%)
C-65.9
(39-87)
96
(55%)
67.8
(21-83)
Positive
McCulloch, 2008
USA (New York) CL  2  (detail)  253
(35%)
C-68.1
(40-95)
214
(66%)
64.6
(34-94)
Positive
McCulloch, 2008
USA (Georgia) CL  2  (detail)  116
(37%)
C-67.3
(40-97)
61
(67%)
68.5
(51-84)
Positive
Morris, 1996
Overlaps with
Benjamin, 1994
CL  2  (detail)  11
(-)
M--99
(-)
-n.a.
Oliveri, 1999
Italy CL  3  (detail)  126
(43%)
C58 + 10.4
(-)
65.8 + 9
(43-87)
119
(52%)
66.3 + 8.5
(50-92)
Negative
Pankratz, 2008
USA (PROGENI, GenePD) CL  2  (detail)  857
(41%)
C61.9 + 10.8
(-)
-867
(60%)
54.8 + 13.1
(-)
Negative
Papapetropoulos, 2007
USA CL  2  (detail)  118
(28%)
N-77 + 7.9
(-)
91
(53%)
79.1 + 12.8
(-)
Positive
Parsian, 2002
USA CL  2  (detail)  285
(35%)
C60
(22-82)
68
(-)
96
(35%)
62 + 14
(-)
Negative
Payami, 2009
Re-analysis of McCulloch, 2008 CL  2  (detail)  ------n.a.
Poduslo, 1995
USA CL  2  (detail)  54
(-)
C-74.1 + 7.5
(-)
77
(-)
71.9 + 7.4
(-)
Negative
Rubinsztein, 1994
UK CL  2  (detail)  34
(24%)
C-57
(-)
34
(-)
-Negative
Schulte, 2003
Germany CL  2  (detail)  457
(46%)
C-67.5 + 10.5
(-)
340
(48%)
72 + 4.3
(-)
Positive
Simon-Sanchez, 2009
USA, Germany (GWAS) CL,PO  1  (detail)  1745
(45%)
C55.8
(7-98)
-4047
(50%)
-Negative
Simon-Sanchez, 2009
USA (NINDS-GWAS) CL  1  (detail)  931
(40%)
C--790
(58%)
-Negative
St.Clair, 1997
UK CL  2  (detail)  58
(33%)
M-78
(69-90)
47
(38%)
78
(67-91)
Negative
Troster, 2006
USA CL  2  (detail)  62
(29%)
C62.7
(-)
68.6
(-)
146
(51%)
71.5 + 7.2
(-)
Positive
Vefring, 2010
Norway CL,PO  2  (detail)  203
(41%)
C-68.2 + 9.1
(-)
187
(47%)
66.2 + 9.6
(-)
Negative
Whitehead, 1996
Ireland PO  2  (detail)  189
(35%)
C45.6 + 7.6
(-)
56.9 + 6.6
(-)
162
(38%)
58 + 7.1
(-)
Negative
Williams-Gray, 2009
UK CL,PO  2  (detail)  528
(40%)
C62.5 + 11.8
(-)
-512
(52%)
-Negative
 Asian
Arai, 1994
Overlaps with
Higuchi, 2000
CL  2  (detail)  49
(-)
---24
(-)
-n.a.
Galasko, 2002
USA (Guam) CL  2  (detail)  11
(55%)
C63.3 + 3.3
(-)
68.4 + 9.8
(-)
403
(-)
-Negative
Higuchi, 2000
Japan CL  2  (detail)  140
(56%)
C-65.5 + 9.5
(-)
382
(69%)
74 + 5.6
(-)
Negative
Kiyohara, 2011
Japan CL  2  (detail)  238
(62%)
C-68.5 + 8.6
(-)
296
(61%)
69.7 + 5.6
(-)
Positive
Pulkes, 2011
Thailand CL  2  (detail)  155
(43%)
C61.2 + 9.8
(40-82)
-158
(-)
-Trend
Ryu, 2010
Korea CL  2  (detail)  234
(71%)
C66.3 + 9.5
(-)
71.1 + 8.2
(-)
192
(49%)
72.2 + 4.9
(-)
Negative
Tang, 2002
China CL  2  (detail)  68
(49%)
C64.4 + 10.3
(-)
65.6 + 5.4
(43-76)
160
(53%)
55.8 + 15.4
(33-95)
Positive
 Hispanic
Gallegos-Arreola, 2009
Mexico CL  2  (detail)  105
(40%)
C-63 + 9
(-)
107
(56%)
50 + 14
(-)
Positive
Lopez, 2007
Mexico CL  2  (detail)  229
(40%)
C54.1 + 12.3
(-)
62.2 + 12.8
(-)
229
(40%)
63.9 + 11.2
(-)
Positive
 Other/Mixed
Clark, 2003
USA CO  1  (detail)  84
(56%)
C-67.8 + 10.3
(-)
458
(64%)
75.7 + 6
(-)
n.a.
Inzelberg, 1998
Israel CL  1  (detail)  78
(22%)
C-72 + 12
(-)
93
(59%)
70 + 13
(-)
Trend
Marder, 1994
USA CL  2  (detail)  57
(-)
C-71.2
(-)
44
(61%)
72.6
(-)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds  
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
 Caucasian
Li, 2004
USA & Australia  2  (detail)  658972
(-)
C--873
(-)
-Positive
Martinez, 2005
USA & Europe  2  (detail)   387
(-)
U--257
(-)
-Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis ->  "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
PDGene Recent Updates
PDGene Top Results
PDGene Stats
Studies: 881
Genes: 915
Polymorphisms: 3446
Meta-analyses: 889
PDGene Links
GEO-PD Meeting 2012
PDmutDB
Curated by the VIB Department of Molecular Genetics of the University of Antwerp
Parkinson's disease Mutation Database
Curated by Parkinson's Institute from Leiden University Medical Center
Mutation Database for Parkinson's Disease
Curated by the Institute for Infocomm Research in Singapore
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.
PD Online Research
Alzheimer Research Forum
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
Copyright © 2014 Biomedical Research Forum LLC Disclaimer Copyright